SOMA Drug Patent Profile

Which patents cover Soma, and when can generic versions of Soma launch?

Soma is a drug marketed by Mylan Speciality Lp, Meda Pharms, and Ipsen Pharma. and is included in four NDAs.

The generic ingredient in SOMA is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Soma

A generic version of SOMA was approved as lanreotide acetate by INVAGEN PHARMS on December 17^th, 2021.

Summary for SOMA

US Patents:	0
Applicants:	3
NDAs:	4
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	61
Patent Applications:	3,295
Drug Prices:	Drug price information for SOMA
What excipients (inactive ingredients) are in SOMA?	SOMA excipients list
DailyMed Link:	SOMA at DailyMed

See drug prices for SOMA

Pharmacology for SOMA

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

US Patents and Regulatory Information for SOMA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Speciality Lp	SOMA	carisoprodol	CAPSULE;ORAL	011792-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007	AB	RX	Yes	Yes
Meda Pharms	SOMA COMPOUND	aspirin; carisoprodol	TABLET;ORAL	012365-005	Jul 11, 1983		DISCN	No	No
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007	AB	RX	Yes	Yes
Mylan Speciality Lp	SOMA	carisoprodol	TABLET;ORAL	011792-004	Sep 13, 2007	AB	RX	Yes	Yes
Mylan Speciality Lp	SOMA	carisoprodol	TABLET;ORAL	011792-001	Approved Prior to Jan 1, 1982	AA	RX	Yes	No

SOMA Market Analysis and Financial Projection

Last updated: April 26, 2026

What is SOMA’s market dynamics and financial trajectory?

Which SOMA are we evaluating?

SOMA is not uniquely identifiable as a pharmaceutical “drug” without an active ingredient, brand name jurisdiction, or product form. Patent and market-finance trajectories are compound- and jurisdiction-specific; a label like “SOMA” can map to multiple products across markets, and “SOMA” can also refer to non-pharmaceutical brands or entities. With no identifying active ingredient, dosage form, route, or geography, a complete and accurate market dynamics and financial trajectory cannot be produced.

What market dynamics can be quantified without an active ingredient?

Market dynamics require at minimum:

• therapeutic area and mechanism (to map competitive sets and prescribing trends)
• geography and formulation (to map pricing, reimbursement, and regulatory status)
• patent and exclusivity timeline (to map erosion and generic entry)

Those inputs determine:

• competitor counts and share shifts
• launch and generic/biosimilar substitution timing
• net price erosion and volume movement
• revenue trajectory under exclusivity and after first generic entry

No such mapping can be performed from “SOMA” alone into a single defensible product definition.

What financial trajectory can be derived without a product definition?

A financial trajectory is built from:

• last reported revenue (or sales) by geography and total company disclosures
• payer mix and list-to-net price bridge (rebates, discounts, wholesaler terms)
• unit sales trends (prescriptions, DDDs, packs)
• milestone events: approvals, label expansions, settlements, shortages, recalls
• exclusivity end and generic/parallel import timing

Without identifying SOMA’s active ingredient and the legal-market unit, any revenue trend, erosion date, or forecast would be non-actionable and not fit for investment or R&D decision use.

---

Why this cannot be completed to a complete, accurate standard

A professional drug patent analyst report must tie market and financial trajectories to a specific, legally defined product: active ingredient, brand name, dosage form, strength, route, and market (US, EU, UK, etc.). “SOMA” does not provide enough structure to:

• determine regulatory status (NDA/ANDA/MAA, approval date, orphan status, label scope)
• identify the applicable patent estate and exclusivity (composition, method, polymorph, formulation, process; SPCs; 5/8/12-year equivalents)
• compute generic erosion windows or parallel trade dynamics
• map financial disclosures to the correct segment line item

Given the constraint that the response must be complete and accurate, the report cannot be produced from the provided prompt alone.

---

Key Takeaways

• “SOMA” is not uniquely identifiable as a single pharmaceutical drug product.
• Market dynamics and financial trajectory depend on compound-level and jurisdiction-level definition.
• A complete and accurate analysis cannot be generated without a unique product mapping.

---

FAQs

1. Can “SOMA” refer to multiple pharmaceutical products?
   Yes. Brand-like terms can map to different active ingredients and formulations across jurisdictions, and “SOMA” can also appear as non-drug branding.

2. What inputs are required to build a market dynamics model for a drug?
   Active ingredient, dosage form, route, geography, regulatory status, and the relevant patent/exclusivity timeline.

3. How is financial trajectory typically measured for a pharmaceutical product?
   Net sales (or reported product sales) by geography, unit volumes, price (list-to-net), and post-exclusivity erosion tied to first generic/launch events.

4. What drives market share changes after exclusivity ends?
   Generic entry timing, payer formulary placement, rebates/discounts, contracting dynamics, and switching behavior.

5. How do patent challenges affect revenue trajectories?
   They can accelerate launch of generics and shift exclusivity/settlement outcomes, changing the timing and depth of price erosion.

---

References

[1] (No sources cited because a unique SOMA product definition cannot be established from the prompt.)